Teva Pharmaceutical Industries (TEVA) Accounts Payables (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Accounts Payables for 18 consecutive years, with $2.6 billion the latest figure, recorded in Q1 2026.

• Quarterly Accounts Payables rose 13.36% year-over-year to $2.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 billion (up 13.36% YoY) and the FY2025 annual result came in at $2.5 billion, up 14.89% from the prior year.
• Accounts Payables improved to $2.6 billion in Q1 2026 per TEVA's latest filing, from $2.5 billion in the prior quarter.
• Over the last five years, Accounts Payables for TEVA reached as high as $2.6 billion in Q4 2023 and fell as low as $1.6 billion in Q3 2022.
• A 5-year average of $2.3 billion and a median of $2.4 billion in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2023 — Accounts Payables jumped 39.45% — and 2024, when it slipped 15.33%.
• Year by year, Accounts Payables stood at $1.9 billion in 2022, then surged by 37.89% to $2.6 billion in 2023, then decreased by 15.33% to $2.2 billion in 2024, then rose by 14.89% to $2.5 billion in 2025, then advanced by 2.57% to $2.6 billion in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $2.6 billion, $2.5 billion, and $2.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.